litlas
Log inCreate account

Franck Morschhauser

Active 2001–2026

236
Papers
29,441
Citations
93
h-index
218
i10-index

Citations

Citations per year for Franck Morschhauser1993: 1 citations2002: 1 citations2003: 6 citations2004: 6 citations2005: 24 citations2006: 20 citations2007: 36 citations2008: 45 citations2009: 50 citations2010: 62 citations2011: 90 citations2012: 99 citations2013: 101 citations2014: 100 citations2015: 152 citations2016: 121 citations2017: 148 citations2018: 209 citations2019: 726 citations2020: 985 citations2021: 1,049 citations2022: 1,067 citations2023: 1,017 citations2024: 1,860 citations2025: 976 citations2026: 14 citations1994–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,557 citing papers, 23.9% of this breakdownChina: 890 citing papers, 8.3% of this breakdownFrance: 790 citing papers, 7.4% of this breakdownGermany: 721 citing papers, 6.7% of this breakdownUnited Kingdom: 675 citing papers, 6.3% of this breakdownItaly: 658 citing papers, 6.1% of this breakdownSwitzerland: 409 citing papers, 3.8% of this breakdownSpain: 398 citing papers, 3.7% of this breakdownCanada: 372 citing papers, 3.5% of this breakdownAustralia: 332 citing papers, 3.1% of this breakdownNetherlands: 291 citing papers, 2.7% of this breakdownJapan: 244 citing papers, 2.3% of this breakdown
0%23.9%Other 22.2%

Institutions

Fields

  • Medicine81.5%
  • Biochemistry, Genetics and Molecular Biology13.1%
  • Immunology and Microbiology3.9%
  • Chemistry0.3%
  • Computer Science0.3%
  • Neuroscience0.2%
  • Other0.7%

Topics

  • Lymphoma Diagnosis and Treatment17.3%
  • CAR-T cell therapy research9.3%
  • Chronic Lymphocytic Leukemia Research6.5%
  • Viral-associated cancers and disorders4.4%
  • CNS Lymphoma Diagnosis and Treatment4.3%
  • Monoclonal and Polyclonal Antibodies Research2.6%
  • Other55.6%

Coauthors

All papers

Open in search
  1. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: Elı́as Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Doǧan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesús F. San Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana H. Advani, Stephen M. Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  2. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Authors: Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wróbel, Fritz Offner, Marek Trněný, Shang‐Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Pérez-Callejo, Linda Lundberg, James Relf, Mark R. Dixon, Emma Clark, Kathryn Humphrey, Martin Hutchings - New England Journal of Medicine 2022 cited by 676

  3. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

    Authors: Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, K. OGASAWARA, Timothy R. Mack, Jeremy S Abramson - The Lancet 2022 cited by 752

  4. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    Authors: Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 cited by 843

  5. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

    Authors: Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, K. OGASAWARA, Manali Kamdar - Blood 2022 cited by 368

  6. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

    Authors: Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Pierre Sesques, Guillaume Manson, Guillaume Cartron, David Beauvais, Louise Roulin, François Xavier Gros, Marie Thérèse Rubio, Pierre Bories, Jacques Olivier Bay, Cristina Castilla Llorente, Sylvain Choquet, Olivier Casasnovas, Mohamad Mohty, Stéphanie Guidez, Magalie Joris, Michaël Loschi, Sylvain Carras, Julie Abraham, Adrien Chauchet, Laurianne Drieu La Rochelle, Bénédicte Deau, Olivier Hermine, Thomas Gastinne, Jean‐Jacques Tudesq, Elodie Gat, Florence Broussais, Catherine Thiéblemont, Roch Houot, Franck Morschhauser - Nature Medicine 2022 cited by 383

  7. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    Authors: Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok‐Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquín Martínez‐López, Antonia Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 cited by 520

  8. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

    Authors: Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pam McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip L. Campbell, Vincent Ribrag, Gandhi Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Shefali Agarwal, Deyaa Adib, Gilles Salles - The Lancet Oncology 2020 cited by 587

  9. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

    Authors: Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo‐Stella, Fritz Offner, Anna Sureda, Gilles Salles, Joaquín Martínez‐López, Michael Crump, Denise Thomas, Peter N. Morcos, Cristiano Ferlini, Ann-Marie E Bröske, Anton Belousov, Marina Bacac, Natalie Dimier, David Carlile, Linda Lundberg, David Pérez-Callejo, Pablo Umaña, Tom Moore, Maja Weisser, Michael Dickinson - Journal of Clinical Oncology 2021 cited by 413

  10. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Authors: Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski and 69 more - The Lancet 2018 cited by 726

  11. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

    Authors: Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, Guillaume Cartron, David Beauvais, Fabien Le Bras, François‐Xavier Gros, Sylvain Choquet, Pierre Bories, Pierre Feugier, Olivier Casasnovas, Jacques Olivier Bay, Mohamad Mohty, Magalie Joris, Thomas Gastinne, Pierre Sesques, Jean‐Jacques Tudesq, Laëtitia Vercellino, Franck Morschhauser, Elodie Gat, Florence Broussais, Roch Houot, Catherine Thiéblemont - Blood 2022 cited by 148

  12. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

    Authors: Emmanuel Bachy, Vincent Camus, Catherine Thiéblemont, David Sibon, Olivier Casasnovas, Loïc Ysebaert, Gandhi Damaj, Stéphanie Guidez, Gian Matteo Pica, Won Seog Kim, Soon Thye Lim, Marc André, Alejandro Martı́n, María Jesús Peñarrubia, Philipp B. Staber, Judith Trotman, Andreas Hüttmann, Vittorio Stefoni, Alessandro Re, Philippe Gaulard, Marie‐Hélène Delfau‐Larue, Laurence de Leval, Michel Meignan, Ju Li, Franck Morschhauser, Richard Delarue - Journal of Clinical Oncology 2021 cited by 192

  13. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

    Authors: Franck Morschhauser, Saurabh Dahiya, M. Lia Palomba, Alejandro Martı́n, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad S. Kahl, Hervé Ghesquières, Kirit M. Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S. Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan P Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia A. Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J. Nastoupil - Nature Medicine 2024 cited by 130

  14. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

    Authors: Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Jean Nichols, Susan Carroll, John Balser, Barbara Balser, Sarah McCue Horwitz - Journal of Clinical Oncology 2012 cited by 674

  15. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

    Authors: Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser - The Lancet Oncology 2015 cited by 335

  16. Management and outcome of primary CNS lymphoma in the modern era

    Authors: Caroline Houillier, Carole Soussain, Hervé Ghesquières, Pierre Soubeyran, Olivier Chinot, Luc Taillandier, T. Lamy, Sylvain Choquet, Guido Ahle, Gandhi Damaj, Philippe Agapé, Cécile Moluçon‐Chabrot, Alexandra Amiel, Vincent Delwail, Michel Fabbro, Fabrice Jardin, Adrien Chauchet, Marie‐Pierre Moles‐Moreau, Franck Morschhauser, Olivier Casasnovas, Rémy Gressin, Luc‐Matthieu Fornecker, Julie Abraham, Jean‐Pierre Marolleau, Adrian Tempescul, Chantal Campello, Philippe Colin, Jérôme Tamburini, Kamel Laribi, Caroline Serrier, Corinne Haïoun, Safia Chebrek, Anna Schmitt, Marie Blonski, Roch Houot, Eileen M. Boyle, Jacques‐Olivier Bay, Lucie Obéric, Émeline Tabouret, Agathe Waultier, N. Martin–Duverneuil, Valérie Touitou, Nathalie Cassoux, Aurélie Kas, Karima Mokhtari, Frédéric Charlotte, Agustí Alentorn, L. Feuvret, Magali Le Garff‐Tavernier, Myrto Costopoulos, Bertrand Mathon, Matthieu Peyre, Daniel Delgadillo, Hassen Douzane, Diane Genet, Bachir Aidaoui, Khê Hoang‐Xuan, Emmanuel Gyan - Neurology 2020 cited by 245

  17. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

    Authors: Jean Lemoine, Emmanuel Bachy, Guillaume Cartron, David Beauvais, Thomas Gastinne, Roberta Di Blasi, Marie‐Thérèse Rubio, Stéphanie Guidez, Mohamad Mohty, Olivier Casasnovas, Magalie Joris, Cristina Castilla‐Llorente, Corinne Haïoun, Olivier Hermine, Michaël Loschi, Sylvain Carras, Pierre Bories, Tom Fradon, Charles Herbaux, Pierre Sesques, Steven Le Gouill, Franck Morschhauser, Catherine Thiéblemont, Roch Houot - Blood Advances 2023 cited by 77

  18. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

    Authors: Michael Wang, Simon Rule, Pier Luigi Zinzani, André Goy, Olivier Casasnovas, Stephen D. Smith, Gandhi Damaj, Jeanette K. Doorduijn, T. Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric D. Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Obéric, Tadeusz Robak, Todd Covey, Richa Dua, Ahmed Hamdy, Xin Huang, Raquel Izumi, Priti Patel, Wayne Rothbaum, J. Greg Slatter, Wojciech Jurczak - The Lancet 2017 cited by 448

  19. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

    Authors: Roch Houot, Emmanuel Bachy, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Lucie Obéric, Thomas Gastinne, Pierre Feugier, Rémy Duléry, Catherine Thiéblemont, Magalie Joris, Fabrice Jardin, Sylvain Choquet, Olivier Casasnovas, Gabriel Brisou, Morgane Cheminant, Jacques‐Olivier Bay, Francisco Llamas Gutierrez, Cédric Menard, Karin Tarte, Marie-Hélène Delfau, Cédric Portugues, Emmanuel Itti, Xavier Palard-Novello, Paul Blanc‐Durand, Yassine Al Tabaa, Clément Bailly, Camille Laurent, François Lemonnier - Nature Medicine 2023 cited by 90

  20. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

    Authors: Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezaï, Patrice Herait, Carmen Kahatt, François Lokiec, Gilles Salles, Thierry Façon, Antonio Palumbo, David Cunningham, Emanuele Zucca, Catherine Thiéblemont - The Lancet Haematology 2016 cited by 428

  21. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

    Authors: Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Panayiotis Panayiotidis, Judit Demeter, Muhıt Özcan, Marina Kosinova, Krimo Bouabdallah, Franck Morschhauser, Don A. Stevens, David R. Trevarthen, Marius Giurescu, Lisa Cupit, Li Liu, Karl Köchert, Henrik Seidel, Carol E. Peña, Shuxin Yin, Florian Hiemeyer, J. Garcia‐Vargas, Barrett H. Childs, Pier Luigi Zinzani - Journal of Clinical Oncology 2017 cited by 398

  22. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

    Authors: Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. Chen, Sarit Assouline, Bruce D. Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lü, Elicia Penuel, Jamie Hirata, Michael Wenger, Yu-Waye Chu, Jeff P. Sharman - The Lancet Haematology 2019 cited by 249

  23. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    Authors: Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles - New England Journal of Medicine 2018 cited by 362

  24. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

    Authors: Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-François Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles Salles, Marek Trněný, Sven de Vos, Farheen Mir, Divya Samineni, Su Y. Kim, Yanwen Jiang, Elizabeth A. Punnoose, Arijit Sinha, Emma Clark, Nathalie Spielewoy, Kathryn Humphrey, Alexandra Bazeos, Andrew D. Zelenetz - Blood 2020 cited by 169